News & Updates

Show Multimedia Only

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

09 May 2025 by

In patients with resectable nonsmall cell lung cancer (NSCLC), adding perioperative durvalumab to neoadjuvant chemotherapy does not appear to have a detrimental impact on patient-reported health-related quality of life (QoL), functioning, or symptoms as compared with neoadjuvant chemotherapy alone, according to data from the phase III AEGEAN study.

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

09 May 2025

MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC

09 May 2025 by

In the protocol-specified final overall survival (OS) analysis of the phase III MARIPOSA trial, treatment with amivantamab plus lazertinib significantly reduced the risk of death in individuals with previously untreated EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).

MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC

09 May 2025

Pain linked to balance, gait issues in COPD

08 May 2025

Individuals with chronic obstructive pulmonary disease (COPD) appear to have poor balance and slower gait speed in the presence of pain, according to a study.

Pain linked to balance, gait issues in COPD

08 May 2025

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

07 May 2025 by

First-line treatment with the combination of fulzerasib and cetuximab appears to induce deep and durable responses in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring KRAS G12C mutation, in addition to having a favourable safety profile, according to the results of the phase II, open-label, single-arm KROCUS trial.

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

07 May 2025

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

07 May 2025 by

A single dose of adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVPreF3 OA) is efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) over three RSV seasons in older adults aged ≥60 years, according to results of the phase III AReSVi-006 trial presented at ESCMID Global 2025.

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

07 May 2025

Therapeutic thoracentesis of no help in patients with acute heart failure, pleural effusion

04 May 2025

A strategy of upfront routine thoracentesis in addition to standard medical therapy does not appear to improve survival outcomes for patients with acute heart failure and pleural effusion, as shown in the results of TAP-IT*.

Therapeutic thoracentesis of no help in patients with acute heart failure, pleural effusion

04 May 2025

Ibrexafungerp expands salvage antifungal treatment options as a pill

03 May 2025 by

For patients with fungal diseases that preclude receiving standard treatment or IV antifungals primarily due to refractoriness or resistance, ibrexafungerp can serve as an effective salvage treatment given orally, offering a positive risk-benefit ratio up to the final data cut-off in the FURI trial

Ibrexafungerp expands salvage antifungal treatment options as a pill

03 May 2025

Breastfeeding reduces risk of infant RTIs

02 May 2025

Infants who have been fully breastfed for 6 months up to at least 1 year appear to have a lower risk of subsequent respiratory tract infections (RTIs) and hospitalization from RTIs, a study has shown.

Breastfeeding reduces risk of infant RTIs

02 May 2025

MSC therapy delivers long-term benefit in severe COVID-19

02 May 2025 by

A recent study suggests patients with severe COVID-19 may benefit from human mesenchymal stem cell (MSC) therapy.

MSC therapy delivers long-term benefit in severe COVID-19

02 May 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

New drug applications approved by US FDA as of 1-15 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

News & Updates

Filter by Specialty:

Specialty:

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

Patient-reported outcome data support perioperative durvalumab for operable NSCLC

MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC

MARIPOSA update: Amivantamab-lazertinib may extend survival beyond 4 years in EGFRm NSCLC

Pain linked to balance, gait issues in COPD

Pain linked to balance, gait issues in COPD

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

Therapeutic thoracentesis of no help in patients with acute heart failure, pleural effusion

Therapeutic thoracentesis of no help in patients with acute heart failure, pleural effusion

Ibrexafungerp expands salvage antifungal treatment options as a pill

Ibrexafungerp expands salvage antifungal treatment options as a pill

Breastfeeding reduces risk of infant RTIs

Breastfeeding reduces risk of infant RTIs

MSC therapy delivers long-term benefit in severe COVID-19

MSC therapy delivers long-term benefit in severe COVID-19

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025